Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 35,500 + web + iconocast  Related to the article below (Last Update: 8/5/2008)

Presstek Reports Second Quarter 2008 Profit; Operating Expenses ...
IT News Online, India - Aug 1, 2008
An archived web cast of this conference call will also be available on the "Investor Events Calendar" page of the company's web site, at . ...PRST
Asian Stocks Decline on Profit, Growth Concerns; Toyota Falls
Bloomberg - Jul 28, 2008
Hanjin, South Korea's largest shipping line, plunged 7 percent to 35500 won, the most since Jan. 30. Nippon Yusen KK, Japan's biggest shipping line, ...TM - SIN:C6L

MLive.com
More antlerless-deer hunting licenses available
MLive.com, MI - Jul 11, 2008
That is a drop from 10200 and 35500 respectively in 2007. Lower Peninsula hunters will have more antlerless licenses available than last year. ...
Satış baskısıyla a?ılan Borsa, toparlanmayı bildi
My Net Haber, Turkey - Jul 10, 2008
A?ılışta 35105 puana kadar gevşeyen Ulusal 100 Endeksi, bir miktar tepki alımı ile 35706 puana kadar y?kseldikten sonra, 35500 civarında yatay seyre girdi ...
Source: Google News

[PDF] Design and Implementation of a Web-based Financial Information System -
JC Watt - 2004 - etd.ils.unc.edu
... Design and Implementation of a Web-based Financial Information System. ... This paper
describes the design and initial implementation of a web-based financial ...
-

Investigation of web stresses in reinforced concrete beams -
FE Richart - ideals.uiuc.edu
... 6 fto 295./ C \omprew5ss/ 2953 44.6's Tesioo in /? Sxeel ^2 0,.SI, "%^ "fl ' D7
5^ L^^ ^^e -T Fm 6"/7> WEB STRESSES IN ... 65 lj"be/-up 05S 35500 39500 274 466 ...

[PDF] … Accumulation of Polychlorinated Biphenyl Congeners in the Terrestrial Food Web of the Kalamazoo … -
AL Blankenship, MJ Zwiernik, KK Coady, DP Kay, JL … - Environmental Science & Technology, 2005 - msu.edu
Differential Accumulation of Polychlorinated Biphenyl Congeners in the Terrestrial
Food Web of the ... This study focused on two locations for food web analysis. ...

Infomaster: an information integration system -
MR Genesereth, AM Keller, OM Duschka - Proceedings of the 1997 ACM SIGMOD international conference …, 1997 - portal.acm.org
... SO, SQL databases through ODBC, EDI transactional and other World Wide Web (WW W ...
hlake Doors Seats Range MSRP 190e Mercedes 4 4 400 35500 450s1 Mercedes 2 2 336 ...

[PDF] A vacuuming-enhanced transaction-time web server -
Y Wang - 2006 - research.wsulibs.wsu.edu
Page 1. A VACUUMING-ENHANCED TRANSACTION-TIME WEB SERVER By Yingxia Wang ... iii Page
4. A VACUUMING-ENHANCED TRANSACTION-TIME WEB SERVER Abstract ...

Translating Implicit Information in the Light of Saussurean, Relevance, and Cognitive Theories
T Farrel, R Hoyle - Notes on Translation, 1995 - ethnologue.com
... Entry number, 35500. ...

HAEMOSTATIC CLIP HOLDER -
M Forster - EP Patent 0,926,991, 2002 - freepatentsonline.com
... than the height of the clip, and normally bearing against the web portion (52 ... generation.
Assignee: Vitalitec, International (13, rue Garengeot, Vitre, 35500, FR ...

[DOC] WEB DESTEKLI DERS ?ALISTIRICI TASARIMI
YDDHI B?LB?L, YDDI BATMAZ, YDDYG SAHIN, ?GM … - tojet.net
WEB DESTEKLI DERS ?ALISTIRICI TASARIMI. ... No:5 35500 Bornova IZMIR-TURKIYE Tel : +90
232 461 41 11(PBX) ext: 305 Fax : +90 232 461 41 21 e-mail: yasar.sahin ...

[CITATION] web GIs ? ??? ??? ??? ???? ????? ??
??

[PDF] Preparations of PAN-based Activated Carbon Nanofiber Web Electrode by Electrostatic Spinning and …
C Kim, JS Kim, WJ Lee, HS Kim, DD Edie, KS Yang - Journal of the Korean Electrochemical Society, 2002 - koixra1.kisti.re.kr
... asspun ? - h? (4] (? oxidativetystabIlized web. + Ae-E/RT (5) 70 ???? ...
????. 4001000 --11?? kkcc -- kkcc --aa SSCC 35500 30000 ...

Source: Google Scholar

Iloperidone Phase III Clinical Data Demonstrate Efficacy And Favorable Safety And Tolerability Profile

 
Titan Pharmaceuticals, Inc. (AMEX: TTP) announced that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile.

These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented by Titan's corporate partner, Vanda Pharmaceuticals, Inc., for the first time this week at a major psychiatric congress. The U.S. Food and Drug Administration (FDA) accepted the NDA submitted by Vanda for marketing approval on November 26, 2007.

The final Phase III study conducted by Vanda evaluated the efficacy of iloperidone versus placebo in patients with schizophrenia. The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24 mg/day, ziprasidone at 160 mg/day, or placebo. Patients treated with iloperidone had significantly greater improvements in Positive and Negative Syndrome Scale-Total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.
Iloperidone and ziprasidone showed similarly low effects on glucose, cholesterol, triglyceride and prolactin levels compared to placebo, and iloperidone was also associated with a favorable profile on the Extrapyramidal Symptoms Rating Scale (ESRS) versus placebo.

Additionally, iloperidone also had a similar akathisia profile to placebo, whereas ziprasidone was associated with a significant worsening of akathisia versus placebo on the Barnes Akathisia Scale (BAS), with 26 percent of patients experiencing a worsening of akathisia. Akathisia is a debilitating sensation of restlessness that can be unrelenting with symptoms that may occur around the clock.

A post-hoc, pooled analysis of three additional Phase III trials was also presented this week. Each trial was a randomized, double-blind, placebo- and active-controlled, parallel-group, six-week trial of patients with schizophrenia or schizoaffective disorder. The analysis evaluated change from baseline using the Brief Psychiatric Rating Scale (BPRS) for the 1,553 patients who remained on treatment for more than two weeks. Iloperidone demonstrated generally significant improvements over placebo in doses ranging from 4-8 mg/day to 20-24 mg/day; similar reductions in BPRS scores were observed at six weeks for iloperidone in doses of 20-24 mg/day, as compared to the active comparators risperidone and haloperidol. The analysis further demonstrated that iloperidone had a favorable safety profile, most notably with regard to extrapyramidal symptoms (EPS) and akathisia rates, weight and metabolic parameters, and prolactin levels.

Unmet Needs in Schizophrenia

Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately one percent of Americans. Although there are many drugs approved to treat schizophrenia, including the commonly prescribed "atypical antipsychotics," a high degree of dissatisfaction remains among physicians and patients. The recent CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, conducted by the National Institute of Mental Health (NIMH) and reported in The New England Journal of Medicine, evaluated several antipsychotic medications and revealed that 74 percent of patients taking antipsychotics discontinued treatment within 18 months, primarily because of insufficient efficacy and tolerability issues.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (AMEX: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders. Titan's products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with government institutions and other leading pharmaceutical development companies.

http://www.titanpharm.com

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

Titan Pharmaceuticals
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.